Gastrinoma Diagnosis and Management

Introduction to Gastrinoma

• The American Gastroenterological Association recommends measuring fasting serum gastrin level after stopping proton pump inhibitors for at least 1 week, confirming gastric pH <2, and obtaining serum calcium and parathyroid hormone levels to evaluate for MEN1 syndrome in patients with a family history of MEN1 presenting with recurrent peptic ulcers, severe GERD, or diarrhea 1, 2

Key Clinical Features

• Severe peptic ulceration affecting the stomach and duodenum, often in atypical locations, occurs in patients with gastrinoma, with approximately 25-40% of gastrinomas occurring in association with MEN1 3, 4

Diagnostic Algorithm

• The American College of Gastroenterology recommends stopping PPIs for at least 1 week before any biochemical testing to avoid false-positive elevated gastrin levels 1, 2, 5
• Fasting serum gastrin level >10 times the upper limit of normal AND gastric pH <2 is diagnostic of gastrinoma 1

MEN1 Evaluation

• The Endocrine Society recommends measuring serum calcium and parathyroid hormone to identify primary hyperparathyroidism, which is present in >90% of MEN1 patients 2
• Primary hyperparathyroidism is usually the first manifestation of MEN1, and its presence mandates a full MEN1 workup 2

Tumor Localization

• The American College of Radiology recommends multiphasic CT or MRI of the abdomen and pelvis as initial imaging for tumor localization, followed by somatostatin receptor scintigraphy (Octreoscan) to detect tumors missed by CT/MRI 5

Prognostic Implications

• Approximately 60% of gastrinomas are malignant with metastases at diagnosis, with a median survival exceeding 10 years and 5-year survival above 80% in surgically resected patients 3, 4
• Complete surgical resection results in 10-year survival of 90% 3
• MEN1-associated gastrinomas are typically multiple and require lifelong surveillance, with a surgical approach that differs from sporadic gastrinomas 2